After viewing a presentation by Sarepta CEO Chris Garabedian, Piper Jaffray believes that the company's Eteplirsen for Duchenne's muscular dystrophy generated "remarkable" data in a Phase IIb study. The firm thinks that eteplirsen meets the criteria for accelerated approval, and it maintains an Overweight rating on the stock.
- Investment & Company Information
- Piper Jaffray
- muscular dystrophy